Rubius Therapeutics (RUBY:NASDAQ) Investor Relations Material

Overview

Rubius Therapeutics, Inc., a prominent biopharmaceutical venture, is devoted to pioneering cutting-edge red cell therapeutics as a means of treating cancer and autoimmune diseases. The firm was once known by the moniker VL26, Inc.; yet, in 2015, underwent a rebranding initiative and adopted its present-day name. Rubius Therapeutics was established in 2013 and is headquartered in Foxborough, Massachusetts.

Annual Reports

Frequently Asked Questions

What is Rubius Therapeutics's ticker?

Rubius Therapeutics's ticker is RUBY

What exchange is Rubius Therapeutics traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Rubius Therapeutics's headquarters?

They are based in Cambridge, Massachusetts

How many employees does Rubius Therapeutics have?

There are 51-200 employees working at Rubius Therapeutics

What is Rubius Therapeutics's website?

It is https://www.rubiustx.com/

What type of sector is Rubius Therapeutics?

Rubius Therapeutics is in the Healthcare sector

What type of industry is Rubius Therapeutics?

Rubius Therapeutics is in the Biotechnology industry

Who are Rubius Therapeutics's peers and competitors?

The following five companies are Rubius Therapeutics's industry peers:

- Arcutis Biotherapeutics

- Kala Pharmaceuticals

- Sunesis Pharmaceuticals, Inc.

- Xtant Medical Holdings

- Diffusion Pharmaceuticals Inc.